Stacy Markel

Nuvation Bio CPO Markel sells 125,000 shares ($753.2K) via scheduled 10b5-1 plan; retains 32.6K shares plus 629,810 options

Stacy Markel, Chief People Officer at Nuvation Bio, sold 125,000 shares at $6.03 under a pre-arranged 10b5-1 trading plan on 2026-06-23, reducing non-derivative holdings to 32.6K shares from 157.6K shares. The sale totaled $753.2K and reflects execution of a scheduled plan rather than a discretionary decision. Markel's cross-ticker track record shows 1 prior open-market buy with 90d return +91.2%, but this ticker-specific transaction at NUVB has only 1 prior measurable event (a 2025-06-18 buy with similar 90d outcome of +91.2%). The company reported annual revenue growth of +699.0% and posted net income of $5.4M in the latest quarter, though it remained unprofitable over the full fiscal year. The stock has appreciated +36.9% over 30 days and +46.2% over 90 days from the transaction date, and currently trades at $6.46, down 33.7% from its 52-week high of $9.75.

Nuvation Bio CPO buys 10,000 shares at $1.71 in cluster pattern; stock down -53.3% from 52-week high amid $-53.2M annual loss.

Markel Stacy, Chief People Officer at Nuvation Bio Inc., purchased 10,000 shares at $1.71 on 2025-06-18, increasing holdings by 51.0% to 29,591 shares total. This transaction occurred amid a broader insider buying cluster of 4 other insiders acquiring shares within the past 14 days, while the stock trades 53.3% below its 52-week high of $3.83 and the company carries a full-year net loss of $-53,236,000.00 against quarterly revenue of $3,084,000.00. The combination of coordinated insider accumulation at depressed valuation levels, concurrent with substantial unprofitability, presents a material data point requiring deeper investigation into whether management's simultaneous buying reflects internal conviction or reflects valuations unrelated to underlying fundamentals.